COMMUNIQUÉ DE PRESSE publié le 29/10/2025 à 13:45, il y a 1 année Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRÈVE publiée le 27/10/2025 à 13:50, il y a 1 année NanoViricides sera présenté à la conférence PODD 2025 NanoViricides NV-387 Biotechnologie Essais Cliniques Médicament Antiviral
BRÈVE publiée le 27/10/2025 à 13:50, il y a 1 année NanoViricides Set to Present at PODD 2025 Conference NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
COMMUNIQUÉ DE PRESSE publié le 27/10/2025 à 13:45, il y a 1 année NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference
BRÈVE publiée le 22/10/2025 à 14:50, il y a 1 année Le NV-387 s'avère prometteur contre la rougeole et protège les poumons NV-387 Essais Cliniques Antiviral Rougeole Protection Pulmonaire
BRÈVE publiée le 22/10/2025 à 14:50, il y a 1 année NV-387 Shows Promise Against Measles, Protects Lungs NV-387 Clinical Trials Antiviral Lung Protection Measles
COMMUNIQUÉ DE PRESSE publié le 22/10/2025 à 14:45, il y a 1 année In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
BRÈVE publiée le 20/10/2025 à 14:50, il y a 1 année NanoViricides Announces Promising Measles Treatment NanoViricides NV-387 Antiviral Drug Measles Treatment Emergency Use
BRÈVE publiée le 20/10/2025 à 14:50, il y a 1 année NanoViricides annonce un traitement prometteur contre la rougeole NanoViricides NV-387 Médicament Antiviral Traitement De La Rougeole Utilisation D'urgence
COMMUNIQUÉ DE PRESSE publié le 20/10/2025 à 14:45, il y a 1 année A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial NanoViricides NV-387 Emergency Use Measles Virus Phase I
Publié le 13/11/2026 à 08:00, il y a 3 heures 37 minutes Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Publié le 12/11/2026 à 23:12, il y a 12 heures 24 minutes Belgrano continues the implementation of its public share buyback offer (OPRA)
Publié le 12/11/2026 à 23:12, il y a 12 heures 24 minutes Belgrano poursuit la mise en oeuvre de son projet d'OPRA
Publié le 12/11/2026 à 23:00, il y a 12 heures 37 minutes Assemblée générale du 12 novembre 2026 : quorum non atteint - Convocation d’une seconde assemblée générale le 27 novembre 2026
Publié le 12/11/2026 à 18:36, il y a 17 heures 1 minute AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Publié le 13/11/2026 à 10:40, il y a 57 minutes SouthGobi Announces Third Quarter 2026 Unaudited Financial and Operating Results
Publié le 13/11/2026 à 09:00, il y a 2 heures 37 minutes Touchstone Exploration Announces Third Quarter 2026 Results
Publié le 13/11/2026 à 02:40, il y a 8 heures 57 minutes Jaguar Mining Reports Third Quarter 2026 Results with 67% Growth in Adjusted Net Income and 46% Higher Adjusted EBITDA
Publié le 13/11/2026 à 02:10, il y a 9 heures 27 minutes Amarc to Participate in Consolidation of Aurora West Through Aurora Minerals LTD
Publié le 12/11/2026 à 23:25, il y a 12 heures 12 minutes Renegade Gold Announces Bought Deal Private Placement for Gross Proceeds of C$5 Million
Publié le 13/11/2026 à 11:01, il y a 36 minutes Finnvera Group, Interim Management Statement 1 January–30 September 2026: Domestic and export financing granted increased year-on-year – Capital buffers will continue to support financing for growth, investments and exports
Publié le 13/11/2026 à 10:34, il y a 1 heure 2 minutes clearvise increases Revenue and Earnings in the third quarter and confirms 2026 full-year forecast
Publié le 13/11/2026 à 10:00, il y a 1 heure 37 minutes Financing Pressures Weigh on Property Stocks as Investor Sentiment Sinks to Lowest Level on Record
Publié le 13/11/2026 à 09:25, il y a 2 heures 12 minutes H&R GmbH & Co. KGaA publishes Interim Report Q3/2026 and confirms Preliminary Figures